Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 7:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 14,387 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Injectable Clear all
Completed Phase 2 Interventional Results available

A Study of TAK-079 in People With Generalized Myasthenia Gravis

NCT04159805
View directory record Official record
Conditions
Myasthenia Gravis
Interventions
TAK-079, TAK-079 Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
27
States / cities
Tucson, Arizona • Palo Alto, California • Sacramento, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2023 · Synced Oct 21, 2026, 7:59 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate Safety and Effectiveness of NOA VOLUME Injectable Gel in Adult Participants Compared to JUVÉDERM VOLUMA XC for Improvement of Mid-Face Volume

NCT06734351
View directory record Official record
Conditions
Mid Face Volume Deficit
Interventions
NOA VOLUME, VOLUMA XC
Device
Lead sponsor
AbbVie
Industry
Eligibility
22 Years and older
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
15
States / cities
Birmingham, Alabama • Glendale, Arizona • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 21, 2026, 7:59 AM EDT
Recruiting Phase 1 Interventional

Brodalumab in the Treatment of Immune-Related Adverse Events

NCT06673329
View directory record Official record
Conditions
Breast Cancer, Esophageal Cancer, Kidney Cancer, Lung Cancer, Thyroid Cancer, Gynecologic Cancer, Pancreatic Cancer, Stomach Cancer, Brain Tumor, Colon Cancer, Rectal Cancer, Head and Neck Cancer, Oral Cancer, Liver Cancer, Skin Cancer, Prostate Cancer, Testicular Cancer, Solid Tumor
Interventions
Brodalumab, CT scan
Drug · Radiation
Lead sponsor
Brian Henick, MD
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 21, 2026, 7:59 AM EDT
Completed Phase 3 Interventional Results available

Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)

NCT02537431
View directory record Official record
Conditions
X-linked Hypophosphatemia
Interventions
burosumab
Biological
Lead sponsor
Kyowa Kirin, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
5
States / cities
San Francisco, California • New Haven, Connecticut • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2024 · Synced Oct 21, 2026, 7:59 AM EDT
Withdrawn Phase 2 Interventional

Alipogene Tiparvovec for the Treatment of LPLD Patients

NCT02904772
View directory record Official record
Conditions
LPL Deficiency
Interventions
alipogene tiparvovec, Prednisolone, Cyclosporins, Mycophenolate mofetil
Drug
Lead sponsor
UniQure Biopharma B.V.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Oct 21, 2026, 7:59 AM EDT
Completed Phase 2 Interventional Results available

Trial of NanoPac Intratumoral Injection in Lung Cancer

NCT04314895
View directory record Official record
Conditions
Lung Cancer, Nonsmall Cell, Lung Cancer, Lung Cancer, Small Cell, Neoplasm of Lung
Interventions
NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension
Drug
Lead sponsor
NanOlogy, LLC
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Gainesville, Florida • Fort Wayne, Indiana • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Oct 21, 2026, 7:59 AM EDT
Completed Phase 3 Interventional Results available

A Study of Ixekizumab in Participants With Active Psoriatic Arthritis

NCT01695239
View directory record Official record
Conditions
Psoriasis, Arthritic
Interventions
Ixekizumab, Placebo, Adalimumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
37
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 34 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Oct 21, 2026, 7:59 AM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Patients With Type 2 Diabetes

NCT00605475
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Canakinumab, Placebo, Metformin
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
6
States / cities
Little Rock, Arkansas • Miami, Florida • MD, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2012 · Synced Oct 21, 2026, 7:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

ADVP005; Dengue CVD 12000 - Dengue-1-Virus Live Virus Human Challenge (DENV-1-LVHC)

NCT04786457
View directory record Official record
Conditions
Dengue
Interventions
Dengue 1 Live Virus Human Challenge (DENV-1-LVHC)
Biological
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Oct 21, 2026, 7:59 AM EDT
Completed Phase 2 Interventional Results available

A Study Designed to Compare 2 Dose Strengths of TI Inhalation Powder in Adults With Type 1 Diabetes Mellitus and to Compare One of Those Formulations (30Units) With an Injection of Insulin Lispro

NCT00662857
View directory record Official record
Conditions
Diabetes Mellitus: Type 1
Interventions
Technosphere Insulin® Inhalation Powder, RAA Population
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 60 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
2
States / cities
Chula Vista, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2014 · Synced Oct 21, 2026, 7:59 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

PK and PD Profile of Dance 501 in Healthy, Non-diabetic Subjects With Mild to Moderate Asthma or COPD

NCT03307512
View directory record Official record
Conditions
Safety and Tolerability
Interventions
inhaled human insulin, Insulin Lispro (Humalog U-100)
Drug
Lead sponsor
Dance Biopharm Inc.
Industry
Eligibility
30 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Sep 13, 2019 · Synced Oct 21, 2026, 7:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First-in-human, Safety, Tolerability, and Pharmacokinetics Study of LXE408 in Healthy Subjects

NCT07809919
View directory record Official record
Conditions
Visceral Leishmaniasis, Chagas Disease
Interventions
LXE408, Placebo, Iohexol
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 21, 2026, 7:59 AM EDT
Recruiting Phase 2 Interventional

A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma

NCT07123090
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma, Metastatic Renal Cancer, Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma, Kidney Cancer, Translocation Renal Cell Carcinoma
Interventions
Sasanlimab, Palbociclib, Axitinib
Drug
Lead sponsor
Stephanie Berg
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 21, 2026, 7:59 AM EDT
Completed Phase 3 Interventional Results available

Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency

NCT02604810
View directory record Official record
Conditions
Primary Immunodeficiency
Interventions
IGIV-C 10%, IGSC 20%
Biological
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
2 Years to 75 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
20
States / cities
Los Angeles, California • Santa Monica, California • Denver, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2019 · Synced Oct 21, 2026, 7:59 AM EDT
Not listed Not applicable Interventional

Use of Autologous Adipose-Derived Stromal Vascular Fraction To Treat Osteoarthritis of Hip, Knee, Ankle, and Thumb Joints

NCT03166410
View directory record Official record
Conditions
Osteoarthritis
Interventions
Cell injection
Procedure
Lead sponsor
Texas Plastic Surgery
Industry
Eligibility
25 Years to 85 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 13, 2020 · Synced Oct 21, 2026, 7:59 AM EDT
Completed Phase 2 Interventional

To Evaluate the Safety, Tolerability and Efficacy of R2R01 Combined With SOC as Compared to SOC Alone in Outpatients With Worsening Heart Failure (WHF)

NCT06264310
View directory record Official record
Conditions
Heart Failure, Worsening Heart Failure (WHF)
Interventions
Placebo, R2R01
Drug
Lead sponsor
River 2 Renal Corp.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
8
States / cities
Fairhope, Alabama • Fort Meyers, Florida • Hialeah, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 21, 2026, 7:59 AM EDT
Active, not recruiting Phase 3 Interventional

Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

NCT04579224
View directory record Official record
Conditions
Metastatic Bladder Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma, Refractory Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8
Interventions
Biospecimen Collection, Bone Scan, Computed Tomography, Docetaxel, Eribulin Mesylate, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Paclitaxel, Sacituzumab Govitecan
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
448
States / cities
Kingman, Arizona • Phoenix, Arizona • Fort Smith, Arkansas + 306 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 21, 2026, 7:59 AM EDT
Completed Phase 1 Interventional

Study of TPI 287 in Patients With Advanced Malignancies

NCT00113724
View directory record Official record
Conditions
Neoplasms, Non-Hodgkin Lymphoma, Hodgkin Disease
Interventions
TPI 287 Injection
Drug
Lead sponsor
Cortice Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
4
States / cities
Tucson, Arizona • Denver, Colorado • Washington D.C., District of Columbia + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2009 · Synced Oct 21, 2026, 7:59 AM EDT
Completed Phase 3 Interventional Results available

An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Previously Untreated Males With Severe Hemophilia A

NCT02234323
View directory record Official record
Conditions
Hemophilia A
Interventions
rFVIIIFc
Biological
Lead sponsor
Bioverativ, a Sanofi company
Industry
Eligibility
Up to 5 Years · Male only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
20
States / cities
Little Rock, Arkansas • Duarte, California • Sacramento, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2022 · Synced Oct 21, 2026, 7:59 AM EDT
Completed Phase 4 Interventional Results available

To Look at the Characteristics of Synovial Fluid and Cartilage Matrix in Osteoarthritic Knee After Hyaluronic Acid Injection

NCT01895959
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Euflexxa, Magnetic Resonance Imaging (MRI)
Drug · Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Oct 21, 2026, 7:59 AM EDT
Completed Not applicable Interventional Results available

The Pediatric Artificial Pancreas (PEDAP) Trial of Control-IQ Technology in Young Children in Type 1 Diabetes

NCT04796779
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Tandem t:slim X2 with Control-IQ Technology Pro, Standard Care (SC), Tandem t:slim X2 with Control-IQ Technology V1.5
Device
Lead sponsor
Marc Breton
Other
Eligibility
24 Months to 71 Months
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Stanford, California • Aurora, Colorado • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 21, 2026, 7:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Basic Assessment of Safety and Minimally Invasive Stimulation Via Injectrode

NCT04672096
View directory record Official record
Conditions
Chronic Lower Limb Pain
Interventions
Neuronoff BASMATI Injectrode
Device
Lead sponsor
Neuronoff, Inc
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 19, 2024 · Synced Oct 21, 2026, 7:59 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Polycystic Ovary Syndrome (PCOS) and Sleep Apnea

NCT00203996
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Obstructive Sleep Apnea
Interventions
continuous positive airway pressure (CPAP), depot leuprolide plus estrogen/progestin replacement, pioglitazone, REM frag, SWS supp
Device · Drug · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 40 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Oct 21, 2026, 7:59 AM EDT
Not listed Phase 3 Interventional

Phase 3 Efficacy and Safety Study of VVZ-149 Injections for Postoperative Pain Following Bunionectomy

NCT04430088
View directory record Official record
Conditions
Pain, Postoperative
Interventions
VVZ-149 Injections, Placebo
Drug
Lead sponsor
Vivozon, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Phoenix, Arizona • Anaheim, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 23, 2020 · Synced Oct 21, 2026, 7:59 AM EDT